NeueHealth, Inc. (NYSE:NEUE - Get Free Report) CEO George Lawrence Mikan III sold 26,660 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $7.19, for a total value of $191,685.40. Following the sale, the chief executive officer now directly owns 178,756 shares in the company, valued at approximately $1,285,255.64. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
George Lawrence Mikan III also recently made the following trade(s):
- On Monday, March 10th, George Lawrence Mikan III sold 1,604 shares of NeueHealth stock. The shares were sold at an average price of $7.06, for a total transaction of $11,324.24.
- On Monday, January 6th, George Lawrence Mikan III sold 31,798 shares of NeueHealth stock. The stock was sold at an average price of $7.33, for a total transaction of $233,079.34.
- On Tuesday, December 17th, George Lawrence Mikan III sold 16,803 shares of NeueHealth stock. The stock was sold at an average price of $4.18, for a total value of $70,236.54.
NeueHealth Trading Up 0.3 %
Shares of NEUE traded up $0.02 during mid-day trading on Tuesday, reaching $6.92. The company had a trading volume of 16,513 shares, compared to its average volume of 24,929. NeueHealth, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $8.32. The firm has a fifty day simple moving average of $7.33 and a 200-day simple moving average of $5.99. The stock has a market cap of $57.33 million, a price-to-earnings ratio of -0.14 and a beta of 0.56.
Analysts Set New Price Targets
Separately, Royal Bank of Canada decreased their target price on shares of NeueHealth from $8.00 to $7.00 and set a "sector perform" rating on the stock in a research report on Monday, December 9th.
Check Out Our Latest Stock Analysis on NEUE
Institutional Investors Weigh In On NeueHealth
A number of institutional investors have recently added to or reduced their stakes in NEUE. Partners Group Holding AG purchased a new position in shares of NeueHealth in the 3rd quarter worth about $463,000. Northern Trust Corp increased its position in NeueHealth by 66.8% during the 4th quarter. Northern Trust Corp now owns 32,644 shares of the company's stock worth $242,000 after purchasing an additional 13,074 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in NeueHealth in the fourth quarter valued at approximately $76,000. Hedge funds and other institutional investors own 63.88% of the company's stock.
NeueHealth Company Profile
(
Get Free Report)
NeueHealth, Inc, a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeueHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeueHealth wasn't on the list.
While NeueHealth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.